Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Total burden of disease in cancer patients at diagnosis-a Danish nationwide study of multimorbidity and redeemed medication

Research output: Contribution to journalJournal articleResearchpeer-review

  1. The role of H1 antihistamines in contralateral breast cancer: a Danish nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Plasma total cell-free DNA is a prognostic biomarker of overall survival in metastatic solid tumour patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Risk of cardiovascular events in men treated for prostate cancer compared with prostate cancer-free men

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Glucose-dependent Insulinotropic Polypeptide (GIP) reduces bone resorption in patients with type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Depressive Symptoms in Danish Patients With Glioma and a Cancer-Free Comparison Group

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. eHealth-mind the gap

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Sexual Function and Quality of Life in a National Cohort of Survivors of Bilateral Testicular Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Multimorbidity is a growing challenge worldwide. In this nationwide study, we investigated the prevalence of multimorbidity and polypharmacy at the time of diagnosis across 20 cancers.

METHODS: We conducted a nationwide register-based cohort study of all Danish residents with a first primary cancer diagnosed between 1 January 2005 and 31 December 2015. Multimorbidity was defined as one or more of 20 conditions (131 specific diagnoses) registered in the Danish National Patient Registry < 5 years before the cancer diagnosis. Polypharmacy was defined as five or more medications registered in the Danish National Prescription Registry and redeemed twice 2-12 months before the cancer diagnosis.

RESULTS: We included 261,745 patients with a first primary cancer, of whom 55% had at least one comorbid condition at diagnosis and 27% had two or more. The most prevalent conditions at the time of cancer diagnosis were cardiovascular disease, chronic obstructive pulmonary disease, diabetes, stroke and depression/anxiety disorder. Polypharmacy was present in one-third of the cancer patients with antihypertensives, anti-thrombotic agents, anti-hyperlipidaemic agents, analgesics and diuretics as the most prevalent redeemed medications.

CONCLUSION: Among patients with a newly established cancer diagnosis, 55% had at least one comorbid condition and 32% were exposed to polypharmacy.

Original languageEnglish
JournalBritish Journal of Cancer
Volume123
Issue number6
Pages (from-to)1033-1040
Number of pages8
ISSN0007-0920
DOIs
Publication statusPublished - Sep 2020

ID: 60921074